In 2020’s EAGLE trial, the PD-L1 inhibitor durvalumab (n = 240), durvalumab plus tremelimumab (a CTLA-4 inhibitor) (n = 247), and the standard of care, defined by the authors as cetuximab, a taxane, methotrexate, or a fluoropyrimidine (n = 249), were compared in patients with R/M HNSCC. Here, CTLA4 is linked to head and neck squamous cell carcinoma.